Nanomaterials: Versatile Drug Carriers for Nanomedicine
293
114. Zhang L, Chen J, Han C (2009) A multicenter clinical trial of recombinant human GM-CSF
hydrogel for the treatment of deep second-degree burns. Wound Repair Regen 17:685–689.
https://doi.org/10.1111/j.1524-475X.2009.00526.x
115. Devi R, Dixit J (2016) Clinical evaluation of insulin like growth factor-I and vascular endothelial growth factor with alloplastic bone graft material in the management of human two. J Clin
diagnostic Res JCDR 10:ZC41
116. Kishimoto Y, Hirano S, Kitani Y, Suehiro A, Umeda H, Tateya I, Kanemaru SI, Tabata Y,
Ito J (2010) Chronic vocal fold scar restoration with hepatocyte growth factor hydrogel.
Laryngoscope 120:108–113. https://doi.org/10.1002/lary.20642
117. Peeters M, Detiger SEL, Karfeld-Sulzer LS, Smit TH, Yayon A, Weber FE, Helder MN
(2015) BMP-2 and BMP-2/7 heterodimers conjugated to a fibrin/hyaluronic acid hydrogel in
a large animal model of mild intervertebral disc degeneration. Biores Open Access 4:398–406.
https://doi.org/10.1089/biores.2015.0025
118. Koda J, Venook A, Walser E, Goodwin S (2002) I/II trial of hepatic intra-arterial delivery
of doxorubicin hydrochloride adsorbed to magnetic targeted carriers in patients with
hepatocellular carcinoma. Eur J Cancer 38:S18–S18
119. Yellen BB, Forbes ZG, Halverson DS, Fridman G, Barbee KA, Chorny M, Levy R, Friedman
G (2005) Targeted drug delivery to magnetic implants for therapeutic applications. J Magn
Magn Mater 293:647–654
120. Escoffre JM, Novell A, de Smet M, Bouakaz A (2013) Focused ultrasound mediated drug
delivery from temperature-sensitive liposomes: in-vitro characterization and validation. Phys
Med Biol 58:8135
121. Tran MA, Gowda R, Sharma A, Park E-J, Adair J, Kester M, Smith NB, Robertson GP
(2008) Targeting V600E B-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits
cutaneous melanocytic lesion development. Cancer Res 68:7638–7649. https://doi.org/10.
1158/0008-5472.CAN-07-6614
122. Stefanadis C, Chrysochoou C, Markou D, Petraki K, Panagiotakos DB, Fasoulakis C, Kyriakidis A, Papadimitriou C, Toutouzas PK (2001) Increased temperature of malignant urinary
bladder tumors in vivo: the application of a new method based on a catheter technique. J Clin
Oncol 19:676–681. https://doi.org/10.1200/JCO.2001.19.3.676
123. Fitzpatrick SD, Fitzpatrick LE, Thakur A, Mazumder MAJ, Sheardown H (2012)
Temperature-sensitive polymers for drug delivery. Expert Rev Med Devices 9:339–351.
https://doi.org/10.1586/erd.12.24
124. Ta T, Porter TM (2013) Thermosensitive liposomes for localized delivery and triggered release
of chemotherapy. J Control Release 169:112–125
125. Iga K, Hamaguchi N, Igari Y, Ogawa Y, Gotoh K, Ootsu K, Toguchi H, Shimamoto T
(1991) Enhanced antitumor activity in mice after administration of thermosensitive liposome
encapsulating cisplatin with hyperthermia. J Pharmacol Exp Ther 257:1203–1207
126. Nishimura Y, Ono K, Hiraoka M, Masunaga S, Jo S, Shibamoto Y, Sasai K, Abe M, Iga
K, Ogawa Y (1990) Treatment of murine SCC VII tumors with localized hyperthermia and
temperature-sensitive liposomes containing cisplatin. Radiat Res 122:161. https://doi.org/10.
2307/3577601
127. Poon E, Harris AL, Ashcroft M (2009) Targeting the hypoxia-inducible factor (HIF) pathway
in cancer. Expert Rev Mol Med 11. https://doi.org/10.1017/S1462399409001173
128. Thambi T, Deepagan VG, Yoon HY, Han HS, Kim SH, Son S, Jo DG, Ahn CH, Suh YD,
Kim K, Kwon IC (2014) Hypoxia-responsive polymeric nanoparticles for tumor-targeted drug
delivery. Biomaterials 35:1735–1743
129. Rapisarda A, Melillo G (2012) Overcoming disappointing results with antiangiogenic therapy
by targeting hypoxia. Nat Rev Clin Oncol 9:378
130. Chiche J, Brahimi-Horn MC, Pouysségur J (2010) Tumour hypoxia induces a metabolic shift
causing acidosis: a common feature in cancer. J Cell Mol Med 14:771–794. https://doi.org/
10.1111/j.1582-4934.2009.00994.x
131. Emmetiere F, Irwin C, Viola-Villegas NT, Longo V, Cheal SM, Zanzonico P, Pillarsetty NVK,
Weber WA, Lewis JS, Reiner T (2013) 18F-labeled-bioorthogonal liposomes for in vivo
targeting. Bioconjug Chem 24:1784–1789. https://doi.org/10.1021/bc400322h
293
114. Zhang L, Chen J, Han C (2009) A multicenter clinical trial of recombinant human GM-CSF
hydrogel for the treatment of deep second-degree burns. Wound Repair Regen 17:685–689.
https://doi.org/10.1111/j.1524-475X.2009.00526.x
115. Devi R, Dixit J (2016) Clinical evaluation of insulin like growth factor-I and vascular endothelial growth factor with alloplastic bone graft material in the management of human two. J Clin
diagnostic Res JCDR 10:ZC41
116. Kishimoto Y, Hirano S, Kitani Y, Suehiro A, Umeda H, Tateya I, Kanemaru SI, Tabata Y,
Ito J (2010) Chronic vocal fold scar restoration with hepatocyte growth factor hydrogel.
Laryngoscope 120:108–113. https://doi.org/10.1002/lary.20642
117. Peeters M, Detiger SEL, Karfeld-Sulzer LS, Smit TH, Yayon A, Weber FE, Helder MN
(2015) BMP-2 and BMP-2/7 heterodimers conjugated to a fibrin/hyaluronic acid hydrogel in
a large animal model of mild intervertebral disc degeneration. Biores Open Access 4:398–406.
https://doi.org/10.1089/biores.2015.0025
118. Koda J, Venook A, Walser E, Goodwin S (2002) I/II trial of hepatic intra-arterial delivery
of doxorubicin hydrochloride adsorbed to magnetic targeted carriers in patients with
hepatocellular carcinoma. Eur J Cancer 38:S18–S18
119. Yellen BB, Forbes ZG, Halverson DS, Fridman G, Barbee KA, Chorny M, Levy R, Friedman
G (2005) Targeted drug delivery to magnetic implants for therapeutic applications. J Magn
Magn Mater 293:647–654
120. Escoffre JM, Novell A, de Smet M, Bouakaz A (2013) Focused ultrasound mediated drug
delivery from temperature-sensitive liposomes: in-vitro characterization and validation. Phys
Med Biol 58:8135
121. Tran MA, Gowda R, Sharma A, Park E-J, Adair J, Kester M, Smith NB, Robertson GP
(2008) Targeting V600E B-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits
cutaneous melanocytic lesion development. Cancer Res 68:7638–7649. https://doi.org/10.
1158/0008-5472.CAN-07-6614
122. Stefanadis C, Chrysochoou C, Markou D, Petraki K, Panagiotakos DB, Fasoulakis C, Kyriakidis A, Papadimitriou C, Toutouzas PK (2001) Increased temperature of malignant urinary
bladder tumors in vivo: the application of a new method based on a catheter technique. J Clin
Oncol 19:676–681. https://doi.org/10.1200/JCO.2001.19.3.676
123. Fitzpatrick SD, Fitzpatrick LE, Thakur A, Mazumder MAJ, Sheardown H (2012)
Temperature-sensitive polymers for drug delivery. Expert Rev Med Devices 9:339–351.
https://doi.org/10.1586/erd.12.24
124. Ta T, Porter TM (2013) Thermosensitive liposomes for localized delivery and triggered release
of chemotherapy. J Control Release 169:112–125
125. Iga K, Hamaguchi N, Igari Y, Ogawa Y, Gotoh K, Ootsu K, Toguchi H, Shimamoto T
(1991) Enhanced antitumor activity in mice after administration of thermosensitive liposome
encapsulating cisplatin with hyperthermia. J Pharmacol Exp Ther 257:1203–1207
126. Nishimura Y, Ono K, Hiraoka M, Masunaga S, Jo S, Shibamoto Y, Sasai K, Abe M, Iga
K, Ogawa Y (1990) Treatment of murine SCC VII tumors with localized hyperthermia and
temperature-sensitive liposomes containing cisplatin. Radiat Res 122:161. https://doi.org/10.
2307/3577601
127. Poon E, Harris AL, Ashcroft M (2009) Targeting the hypoxia-inducible factor (HIF) pathway
in cancer. Expert Rev Mol Med 11. https://doi.org/10.1017/S1462399409001173
128. Thambi T, Deepagan VG, Yoon HY, Han HS, Kim SH, Son S, Jo DG, Ahn CH, Suh YD,
Kim K, Kwon IC (2014) Hypoxia-responsive polymeric nanoparticles for tumor-targeted drug
delivery. Biomaterials 35:1735–1743
129. Rapisarda A, Melillo G (2012) Overcoming disappointing results with antiangiogenic therapy
by targeting hypoxia. Nat Rev Clin Oncol 9:378
130. Chiche J, Brahimi-Horn MC, Pouysségur J (2010) Tumour hypoxia induces a metabolic shift
causing acidosis: a common feature in cancer. J Cell Mol Med 14:771–794. https://doi.org/
10.1111/j.1582-4934.2009.00994.x
131. Emmetiere F, Irwin C, Viola-Villegas NT, Longo V, Cheal SM, Zanzonico P, Pillarsetty NVK,
Weber WA, Lewis JS, Reiner T (2013) 18F-labeled-bioorthogonal liposomes for in vivo
targeting. Bioconjug Chem 24:1784–1789. https://doi.org/10.1021/bc400322h